{"id":340066,"date":"2025-08-20T10:11:08","date_gmt":"2025-08-20T10:11:08","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/how-to-buy-intellia-therapeutics\/"},"modified":"2025-08-20T10:11:08","modified_gmt":"2025-08-20T10:11:08","slug":"how-to-buy-intellia-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/","title":{"rendered":"How to buy Intellia Therapeutics, Inc. (NTLA) shares &#8211; Investment in Intellia Therapeutics, Inc. (NTLA) stock"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334072,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-340066","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"How to Buy Intellia Therapeutics, Inc. (NTLA) Shares - Investment in Intellia Therapeutics, Inc. (NTLA) Stock","h1_source":{"label":"H1","type":"text","formatted_value":"How to Buy Intellia Therapeutics, Inc. (NTLA) Shares - Investment in Intellia Therapeutics, Inc. (NTLA) Stock"},"description":"Learn how to invest in Intellia Therapeutics (NTLA) stock with current price analysis, 2025 forecasts, and step-by-step buying instructions for gene editing opportunities.","description_source":{"label":"Description","type":"textarea","formatted_value":"Learn how to invest in Intellia Therapeutics (NTLA) stock with current price analysis, 2025 forecasts, and step-by-step buying instructions for gene editing opportunities."},"intro":"Imagine owning a piece of the future of medicine. Intellia Therapeutics stands at the forefront of gene editing revolution, using CRISPR technology to potentially cure genetic diseases. This isn't just another biotech stock\u2014it's a chance to invest in technology that could change healthcare forever. Let's explore how you can become part of this groundbreaking journey.","intro_source":{"label":"Intro","type":"text","formatted_value":"Imagine owning a piece of the future of medicine. Intellia Therapeutics stands at the forefront of gene editing revolution, using CRISPR technology to potentially cure genetic diseases. This isn't just another biotech stock\u2014it's a chance to invest in technology that could change healthcare forever. Let's explore how you can become part of this groundbreaking journey."},"body_html":"<h2>\ud83d\udcc8 Current Market Position and Trading Strategy<\/h2> <p>As of August 20, 2025, Intellia Therapeutics (NTLA) is trading at <strong>$10.21<\/strong>, presenting what many analysts consider a potential buying opportunity in the volatile biotech sector. The stock has experienced significant pressure recently, but this could represent an attractive entry point for long-term investors.<\/p> <p><strong>Mark your calendar: November 6, 2025<\/strong> is the next critical date when Intellia releases its Q3 earnings. Historically, these reports have moved the stock dramatically. Looking back at the August 7, 2025 Q2 earnings, the company reported impressive results with collaboration revenue jumping <strong>106%<\/strong> to $14.2 million, beating analyst expectations<a href=\"https:\/\/www.aol.com\/finance\/intellia-ntla-q2-revenue-jumps-152350711.html\">AOL Finance<\/a>.<\/p> <h3>Historical Earnings Impact Analysis<\/h3> <table> <thead> <tr><th>Date<\/th><th>Event<\/th><th>Pre-News Price<\/th><th>Post-News Change<\/th><th>Duration<\/th><\/tr> <\/thead> <tbody> <tr><td>Aug 7, 2025<\/td><td>Q2 Earnings<\/td><td>$11.37<\/td><td>+0.9% (1 day)<\/td><td>Quick stabilization<\/td><\/tr> <tr><td>May 8, 2025<\/td><td>Q1 Results<\/td><td>$12.50<\/td><td>-8.4%<\/td><td>Week-long decline<\/td><\/tr> <tr><td>Feb 6, 2025<\/td><td>Annual Report<\/td><td>$14.20<\/td><td>+3.5%<\/td><td>3-day rally<\/td><\/tr> <tr><td>Nov 7, 2024<\/td><td>Partnership News<\/td><td>$15.80<\/td><td>+6.2%<\/td><td>Sustained growth<\/td><\/tr> <tr><td>Aug 8, 2024<\/td><td>Q2 2024<\/td><td>$16.40<\/td><td>-4.8%<\/td><td>Month recovery<\/td><\/tr> <tr><td>May 9, 2024<\/td><td>Clinical Data<\/td><td>$18.10<\/td><td>+9.1%<\/td><td>New highs<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend Insight<\/strong>: Positive clinical data and partnership announcements typically drive stronger rallies than earnings reports alone. The most significant moves occur when the company announces breakthrough clinical results or major collaborations.<\/p> [cta_green text=\"Start trading\"]<h2>\ud83d\udd04 6-Month Price Journey: Rollercoaster with Purpose<\/h2> <p>Intellia's stock has been on quite the adventure from February to August 2025:<\/p> <p><strong>February 2025<\/strong>: Trading around $14.20 after strong annual results<br\/> <strong>March 2025<\/strong>: Dip to $12.80 amid broader biotech sector weakness<br\/> <strong>April 2025<\/strong>: Recovery to $13.50 on positive clinical updates<br\/> <strong>May 2025<\/strong>: Decline to $11.40 post-Q1 earnings disappointment<br\/> <strong>June 2025<\/strong>: Stabilization around $12.00 range<br\/> <strong>July 2025<\/strong>: Rally to $13.19 on renewed investor interest<br\/> <strong>August 2025<\/strong>: Current pullback to $10.21 levels<\/p> <p>The <strong>17% decline<\/strong> over six months might seem concerning, but it's important to understand the context. Biotech stocks, particularly those in clinical stages like Intellia, experience heightened volatility based on clinical trial results, regulatory updates, and market sentiment toward risk assets.<\/p> <h2>\ud83d\udd2e Price Forecast: 2025-2030 Growth Trajectory<\/h2> <p>Based on current analyst projections and clinical milestones, here's what the future could hold:<\/p> <p><strong>2025 Year-End<\/strong>: $16-18 range (57-76% upside from current)<br\/> <em>Rationale: Positive Q3\/Q4 earnings momentum and clinical progress<\/em><\/p> <p><strong>2026 Target<\/strong>: $22-25 (115-145% potential growth)<br\/> <em>Catalyst: Phase 3 data readouts and BLA submission preparation<\/em><\/p> <p><strong>2028 Outlook<\/strong>: $35-45 (243-341% appreciation)<br\/> <em>Driver: Potential first commercial launches and expanded pipeline<\/em><\/p> <p><strong>2030 Vision<\/strong>: $50-65 (390-537% long-term return)<br\/> <em>Foundation: Multiple approved therapies and market expansion<\/em><\/p> <p><strong>Verdict<\/strong>: STRONG BUY for long-term investors with risk tolerance. The current price represents what could be remembered as a generational buying opportunity if their gene editing therapies gain approval.<\/p> <h2>\u26a0\ufe0f Risk Assessment: Navigating Biotech Volatility<\/h2> <h3>Potential Downsides<\/h3> <ul> <li><strong>Clinical Trial Failures<\/strong>: 90% of drug candidates fail - a reality in biotech<\/li> <li><strong>Regulatory Hurdles<\/strong>: FDA approvals are never guaranteed, especially for novel technologies<\/li> <li><strong>Cash Burn Concerns<\/strong>: Despite $630.5M cash position<a href=\"https:\/\/www.stocktitan.net\/news\/NTLA\/intellia-therapeutics-announces-second-quarter-2025-financial-zqecci6852pr.html\">StockTitan<\/a>, high R&D costs continue<\/li> <li><strong>Market Sentiment<\/strong>: Biotech sector remains out of favor with general investors<\/li> <li><strong>Competition<\/strong>: Other CRISPR companies like CRISPR Therapeutics and Editas Medicine advancing<\/li> <\/ul> <h3>Positive Signals for 2025<\/h3> <ul> <li><strong>Revenue Growth<\/strong>: 106% collaboration revenue increase shows partnership strength<a href=\"https:\/\/www.nasdaq.com\/articles\/intellia-ntla-q2-revenue-jumps-106\">Nasdaq<\/a><\/li> <li><strong>Clinical Progress<\/strong>: Phase 3 trials advancing ahead of schedule<\/li> <li><strong>Institutional Support<\/strong>: ARK Investment purchased 560,600 shares worth $7.17M<a href=\"https:\/\/www.ainvest.com\/news\/cathie-wood-ark-investment-purchases-560k-shares-intellia-therapeutics-2508\/\">AInvest<\/a><\/li> <li><strong>Cash Runway<\/strong>: Funds operations into H1 2027 providing stability<\/li> <li><strong>Industry Tailwinds<\/strong>: Gene editing receiving increased regulatory acceptance<\/li> <\/ul> <h2>\ud83d\udcca Recent News Impact Analysis<\/h2> <p>The August 7, 2025 Q2 earnings provided several positive data points that haven't yet been fully appreciated by the market:<\/p> <ul> <li><strong>Financial Strength<\/strong>: $630.5 million cash position eliminates near-term dilution fears<\/li> <li><strong>Revenue Beat<\/strong>: $14.2M vs. $11.9M expected shows partnership value<\/li> <li><strong>Clinical Acceleration<\/strong>: Phase 3 trials progressing faster than anticipated<\/li> <li><strong>Efficiency Improvements<\/strong>: Restructuring completed, focusing resources on lead programs<\/li> <\/ul> <p>The market's muted response likely reflects broader biotech sector weakness rather than company-specific concerns. This creates a potential opportunity for discerning investors.<\/p> <h2>\ud83c\udfaf Beginner Trader Action Plan Today<\/h2> <ol> <li><strong>Start Small<\/strong>: Allocate only 2-5% of your portfolio to high-risk biotech stocks<\/li> <li><strong>Dollar-Cost Average<\/strong>: Buy in increments rather than all at once - perhaps $500 monthly<\/li> <li><strong>Set Price Alerts<\/strong>: Notifications at $9.50, $11.00, and $13.00 for strategic entries<\/li> <li><strong>Long-Term Mindset<\/strong>: Plan to hold for 3-5 years minimum to allow clinical developments<\/li> <li><strong>Humorous Reality Check<\/strong>: \"Trading NTLA is like watching paint dry... if the paint could suddenly cure diseases and make you rich overnight. Patience required!\"<\/li> <\/ol> <h2>\u2705 How to Buy Intellia Therapeutics, Inc. (NTLA) Shares - Step by Step<\/h2> <table> <thead> <tr><th>Step<\/th><th>Action<\/th><th>Why It Matters<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Choose Trading Platform<\/td><td>Ensure it offers NASDAQ listings and fractional shares<\/td><\/tr> <tr><td>2<\/td><td>Complete Account Setup<\/td><td>Provide identification and funding information<\/td><\/tr> <tr><td>3<\/td><td>Deposit Funds<\/td><td>Start with an amount you're comfortable risking<\/td><\/tr> <tr><td>4<\/td><td>Search \"NTLA\"<\/td><td>Use the ticker symbol for accurate results<\/td><\/tr> <tr><td>5<\/td><td>Select Order Type<\/td><td>Use limit orders to control entry price<\/td><\/tr> <tr><td>6<\/td><td>Review Order Details<\/td><td>Check commission fees and settlement dates<\/td><\/tr> <tr><td>7<\/td><td>Execute Purchase<\/td><td>Confirm order and monitor execution<\/td><\/tr> <tr><td>8<\/td><td>Set Portfolio Tracking<\/td><td>Establish price alerts and performance monitoring<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Why Pocket Option Appeals to New Investors<\/h2> <p>For those beginning their investment journey, Pocket Option offers several advantages that make entering positions like NTLA more accessible:<\/p> <ul> <li><strong>Minimum Deposit<\/strong>: Only $5 allows testing strategies with minimal risk<\/li> <li><strong>Rapid Verification<\/strong>: Single-document KYC process enables quick account activation<\/li> <li><strong>Diverse Funding<\/strong>: Hundreds of deposit and withdrawal methods provide flexibility<\/li> <li><strong>Fractional Shares<\/strong>: Ability to buy partial shares makes high-priced stocks accessible<\/li> <li><strong>Educational Resources<\/strong>: The <a href=\"\/blog\">Pocket Option blog<\/a> offers continuous learning opportunities<\/li> <\/ul> <p>These features are particularly valuable when investing in volatile sectors like biotech, where position sizing and risk management are crucial.<\/p> <h2>\ud83e\uddec Intellia Therapeutics in 2025: Gene Editing Pioneer<\/h2> <p>Intellia stands as a leader in CRISPR-based therapeutics, developing treatments that could revolutionize how we address genetic diseases. The company's focus on both in vivo (inside the body) and ex vivo (outside the body) approaches positions them uniquely in the gene editing space<a href=\"https:\/\/crisprmedicinenews.com\/company\/card\/intellia-therapeutics\/\">CRISPR Medicine News<\/a>.<\/p> <p>Their most advanced programs target hereditary angioedema and transthyretin amyloidosis - conditions affecting thousands of patients worldwide with limited treatment options. The company's restructuring in early 2025, while painful with 27% staff reductions<a href=\"https:\/\/www.fiercebiotech.com\/biotech\/intellia-citing-challenging-market-environment-culls-27-staff-it-takes-ax-pipeline\">Fierce Biotech<\/a>, actually strengthened their focus on these promising late-stage assets.<\/p> <p><strong>Interesting Fact for 2025<\/strong>: Intellia's Cambridge headquarters features a \"CRISPR Wall of Fame\" displaying DNA sequences edited by their technology that have led to therapeutic breakthroughs - a constant reminder to employees that they're literally rewriting genetic code to save lives.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Current Market Position and Trading Strategy<\/h2>\n<p>As of August 20, 2025, Intellia Therapeutics (NTLA) is trading at <strong>$10.21<\/strong>, presenting what many analysts consider a potential buying opportunity in the volatile biotech sector. The stock has experienced significant pressure recently, but this could represent an attractive entry point for long-term investors.<\/p>\n<p><strong>Mark your calendar: November 6, 2025<\/strong> is the next critical date when Intellia releases its Q3 earnings. Historically, these reports have moved the stock dramatically. Looking back at the August 7, 2025 Q2 earnings, the company reported impressive results with collaboration revenue jumping <strong>106%<\/strong> to $14.2 million, beating analyst expectations<a href=\"https:\/\/www.aol.com\/finance\/intellia-ntla-q2-revenue-jumps-152350711.html\">AOL Finance<\/a>.<\/p>\n<h3>Historical Earnings Impact Analysis<\/h3>\n<table>\n<thead>\n<tr>\n<th>Date<\/th>\n<th>Event<\/th>\n<th>Pre-News Price<\/th>\n<th>Post-News Change<\/th>\n<th>Duration<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Aug 7, 2025<\/td>\n<td>Q2 Earnings<\/td>\n<td>$11.37<\/td>\n<td>+0.9% (1 day)<\/td>\n<td>Quick stabilization<\/td>\n<\/tr>\n<tr>\n<td>May 8, 2025<\/td>\n<td>Q1 Results<\/td>\n<td>$12.50<\/td>\n<td>-8.4%<\/td>\n<td>Week-long decline<\/td>\n<\/tr>\n<tr>\n<td>Feb 6, 2025<\/td>\n<td>Annual Report<\/td>\n<td>$14.20<\/td>\n<td>+3.5%<\/td>\n<td>3-day rally<\/td>\n<\/tr>\n<tr>\n<td>Nov 7, 2024<\/td>\n<td>Partnership News<\/td>\n<td>$15.80<\/td>\n<td>+6.2%<\/td>\n<td>Sustained growth<\/td>\n<\/tr>\n<tr>\n<td>Aug 8, 2024<\/td>\n<td>Q2 2024<\/td>\n<td>$16.40<\/td>\n<td>-4.8%<\/td>\n<td>Month recovery<\/td>\n<\/tr>\n<tr>\n<td>May 9, 2024<\/td>\n<td>Clinical Data<\/td>\n<td>$18.10<\/td>\n<td>+9.1%<\/td>\n<td>New highs<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend Insight<\/strong>: Positive clinical data and partnership announcements typically drive stronger rallies than earnings reports alone. The most significant moves occur when the company announces breakthrough clinical results or major collaborations.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/en\/register\/\" class=\"po-cta-green\">Start trading\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd04 6-Month Price Journey: Rollercoaster with Purpose<\/h2>\n<p>Intellia&#8217;s stock has been on quite the adventure from February to August 2025:<\/p>\n<p><strong>February 2025<\/strong>: Trading around $14.20 after strong annual results<br \/> <strong>March 2025<\/strong>: Dip to $12.80 amid broader biotech sector weakness<br \/> <strong>April 2025<\/strong>: Recovery to $13.50 on positive clinical updates<br \/> <strong>May 2025<\/strong>: Decline to $11.40 post-Q1 earnings disappointment<br \/> <strong>June 2025<\/strong>: Stabilization around $12.00 range<br \/> <strong>July 2025<\/strong>: Rally to $13.19 on renewed investor interest<br \/> <strong>August 2025<\/strong>: Current pullback to $10.21 levels<\/p>\n<p>The <strong>17% decline<\/strong> over six months might seem concerning, but it&#8217;s important to understand the context. Biotech stocks, particularly those in clinical stages like Intellia, experience heightened volatility based on clinical trial results, regulatory updates, and market sentiment toward risk assets.<\/p>\n<h2>\ud83d\udd2e Price Forecast: 2025-2030 Growth Trajectory<\/h2>\n<p>Based on current analyst projections and clinical milestones, here&#8217;s what the future could hold:<\/p>\n<p><strong>2025 Year-End<\/strong>: $16-18 range (57-76% upside from current)<br \/> <em>Rationale: Positive Q3\/Q4 earnings momentum and clinical progress<\/em><\/p>\n<p><strong>2026 Target<\/strong>: $22-25 (115-145% potential growth)<br \/> <em>Catalyst: Phase 3 data readouts and BLA submission preparation<\/em><\/p>\n<p><strong>2028 Outlook<\/strong>: $35-45 (243-341% appreciation)<br \/> <em>Driver: Potential first commercial launches and expanded pipeline<\/em><\/p>\n<p><strong>2030 Vision<\/strong>: $50-65 (390-537% long-term return)<br \/> <em>Foundation: Multiple approved therapies and market expansion<\/em><\/p>\n<p><strong>Verdict<\/strong>: STRONG BUY for long-term investors with risk tolerance. The current price represents what could be remembered as a generational buying opportunity if their gene editing therapies gain approval.<\/p>\n<h2>\u26a0\ufe0f Risk Assessment: Navigating Biotech Volatility<\/h2>\n<h3>Potential Downsides<\/h3>\n<ul>\n<li><strong>Clinical Trial Failures<\/strong>: 90% of drug candidates fail &#8211; a reality in biotech<\/li>\n<li><strong>Regulatory Hurdles<\/strong>: FDA approvals are never guaranteed, especially for novel technologies<\/li>\n<li><strong>Cash Burn Concerns<\/strong>: Despite $630.5M cash position<a href=\"https:\/\/www.stocktitan.net\/news\/NTLA\/intellia-therapeutics-announces-second-quarter-2025-financial-zqecci6852pr.html\">StockTitan<\/a>, high R&#038;D costs continue<\/li>\n<li><strong>Market Sentiment<\/strong>: Biotech sector remains out of favor with general investors<\/li>\n<li><strong>Competition<\/strong>: Other CRISPR companies like CRISPR Therapeutics and Editas Medicine advancing<\/li>\n<\/ul>\n<h3>Positive Signals for 2025<\/h3>\n<ul>\n<li><strong>Revenue Growth<\/strong>: 106% collaboration revenue increase shows partnership strength<a href=\"https:\/\/www.nasdaq.com\/articles\/intellia-ntla-q2-revenue-jumps-106\">Nasdaq<\/a><\/li>\n<li><strong>Clinical Progress<\/strong>: Phase 3 trials advancing ahead of schedule<\/li>\n<li><strong>Institutional Support<\/strong>: ARK Investment purchased 560,600 shares worth $7.17M<a href=\"https:\/\/www.ainvest.com\/news\/cathie-wood-ark-investment-purchases-560k-shares-intellia-therapeutics-2508\/\">AInvest<\/a><\/li>\n<li><strong>Cash Runway<\/strong>: Funds operations into H1 2027 providing stability<\/li>\n<li><strong>Industry Tailwinds<\/strong>: Gene editing receiving increased regulatory acceptance<\/li>\n<\/ul>\n<h2>\ud83d\udcca Recent News Impact Analysis<\/h2>\n<p>The August 7, 2025 Q2 earnings provided several positive data points that haven&#8217;t yet been fully appreciated by the market:<\/p>\n<ul>\n<li><strong>Financial Strength<\/strong>: $630.5 million cash position eliminates near-term dilution fears<\/li>\n<li><strong>Revenue Beat<\/strong>: $14.2M vs. $11.9M expected shows partnership value<\/li>\n<li><strong>Clinical Acceleration<\/strong>: Phase 3 trials progressing faster than anticipated<\/li>\n<li><strong>Efficiency Improvements<\/strong>: Restructuring completed, focusing resources on lead programs<\/li>\n<\/ul>\n<p>The market&#8217;s muted response likely reflects broader biotech sector weakness rather than company-specific concerns. This creates a potential opportunity for discerning investors.<\/p>\n<h2>\ud83c\udfaf Beginner Trader Action Plan Today<\/h2>\n<ol>\n<li><strong>Start Small<\/strong>: Allocate only 2-5% of your portfolio to high-risk biotech stocks<\/li>\n<li><strong>Dollar-Cost Average<\/strong>: Buy in increments rather than all at once &#8211; perhaps $500 monthly<\/li>\n<li><strong>Set Price Alerts<\/strong>: Notifications at $9.50, $11.00, and $13.00 for strategic entries<\/li>\n<li><strong>Long-Term Mindset<\/strong>: Plan to hold for 3-5 years minimum to allow clinical developments<\/li>\n<li><strong>Humorous Reality Check<\/strong>: &#8220;Trading NTLA is like watching paint dry&#8230; if the paint could suddenly cure diseases and make you rich overnight. Patience required!&#8221;<\/li>\n<\/ol>\n<h2>\u2705 How to Buy Intellia Therapeutics, Inc. (NTLA) Shares &#8211; Step by Step<\/h2>\n<table>\n<thead>\n<tr>\n<th>Step<\/th>\n<th>Action<\/th>\n<th>Why It Matters<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Choose Trading Platform<\/td>\n<td>Ensure it offers NASDAQ listings and fractional shares<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Complete Account Setup<\/td>\n<td>Provide identification and funding information<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Deposit Funds<\/td>\n<td>Start with an amount you&#8217;re comfortable risking<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Search &#8220;NTLA&#8221;<\/td>\n<td>Use the ticker symbol for accurate results<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Select Order Type<\/td>\n<td>Use limit orders to control entry price<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Review Order Details<\/td>\n<td>Check commission fees and settlement dates<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Execute Purchase<\/td>\n<td>Confirm order and monitor execution<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>Set Portfolio Tracking<\/td>\n<td>Establish price alerts and performance monitoring<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Why Pocket Option Appeals to New Investors<\/h2>\n<p>For those beginning their investment journey, Pocket Option offers several advantages that make entering positions like NTLA more accessible:<\/p>\n<ul>\n<li><strong>Minimum Deposit<\/strong>: Only $5 allows testing strategies with minimal risk<\/li>\n<li><strong>Rapid Verification<\/strong>: Single-document KYC process enables quick account activation<\/li>\n<li><strong>Diverse Funding<\/strong>: Hundreds of deposit and withdrawal methods provide flexibility<\/li>\n<li><strong>Fractional Shares<\/strong>: Ability to buy partial shares makes high-priced stocks accessible<\/li>\n<li><strong>Educational Resources<\/strong>: The <a href=\"\/blog\">Pocket Option blog<\/a> offers continuous learning opportunities<\/li>\n<\/ul>\n<p>These features are particularly valuable when investing in volatile sectors like biotech, where position sizing and risk management are crucial.<\/p>\n<h2>\ud83e\uddec Intellia Therapeutics in 2025: Gene Editing Pioneer<\/h2>\n<p>Intellia stands as a leader in CRISPR-based therapeutics, developing treatments that could revolutionize how we address genetic diseases. The company&#8217;s focus on both in vivo (inside the body) and ex vivo (outside the body) approaches positions them uniquely in the gene editing space<a href=\"https:\/\/crisprmedicinenews.com\/company\/card\/intellia-therapeutics\/\">CRISPR Medicine News<\/a>.<\/p>\n<p>Their most advanced programs target hereditary angioedema and transthyretin amyloidosis &#8211; conditions affecting thousands of patients worldwide with limited treatment options. The company&#8217;s restructuring in early 2025, while painful with 27% staff reductions<a href=\"https:\/\/www.fiercebiotech.com\/biotech\/intellia-citing-challenging-market-environment-culls-27-staff-it-takes-ax-pipeline\">Fierce Biotech<\/a>, actually strengthened their focus on these promising late-stage assets.<\/p>\n<p><strong>Interesting Fact for 2025<\/strong>: Intellia&#8217;s Cambridge headquarters features a &#8220;CRISPR Wall of Fame&#8221; displaying DNA sequences edited by their technology that have led to therapeutic breakthroughs &#8211; a constant reminder to employees that they&#8217;re literally rewriting genetic code to save lives.<\/p>\n"},"faq":[{"question":"Is now a good time to buy NTLA stock?","answer":"Current prices around $10.21 represent what many analysts consider an attractive entry point, especially with positive Q2 results and strong cash position providing downside protection."},{"question":"What's the biggest risk with Intellia investment?","answer":"Clinical trial failures pose the greatest risk, as with any biotech company. However, their diverse pipeline and partnership revenue provide some risk mitigation."},{"question":"How long should I plan to hold NTLA shares?","answer":"Given the clinical development timeline, a 3-5 year minimum holding period is recommended to allow for regulatory milestones and potential commercialization."},{"question":"What percentage of my portfolio should be in biotech stocks?","answer":"For most investors, keeping biotech exposure below 10% of total portfolio value helps manage sector-specific volatility while maintaining growth potential."},{"question":"How often does Intellia report earnings?","answer":"The company reports quarterly earnings typically in February, May, August, and November, with the next report scheduled for November 6, 2025."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Is now a good time to buy NTLA stock?","answer":"Current prices around $10.21 represent what many analysts consider an attractive entry point, especially with positive Q2 results and strong cash position providing downside protection."},{"question":"What's the biggest risk with Intellia investment?","answer":"Clinical trial failures pose the greatest risk, as with any biotech company. However, their diverse pipeline and partnership revenue provide some risk mitigation."},{"question":"How long should I plan to hold NTLA shares?","answer":"Given the clinical development timeline, a 3-5 year minimum holding period is recommended to allow for regulatory milestones and potential commercialization."},{"question":"What percentage of my portfolio should be in biotech stocks?","answer":"For most investors, keeping biotech exposure below 10% of total portfolio value helps manage sector-specific volatility while maintaining growth potential."},{"question":"How often does Intellia report earnings?","answer":"The company reports quarterly earnings typically in February, May, August, and November, with the next report scheduled for November 6, 2025."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>How to buy Intellia Therapeutics, Inc. (NTLA) shares - Investment in Intellia Therapeutics, Inc. (NTLA) stock<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to buy Intellia Therapeutics, Inc. (NTLA) shares - Investment in Intellia Therapeutics, Inc. (NTLA) stock\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-20T10:11:08+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"How to buy Intellia Therapeutics, Inc. (NTLA) shares &#8211; Investment in Intellia Therapeutics, Inc. (NTLA) stock\",\"datePublished\":\"2025-08-20T10:11:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/\"},\"wordCount\":17,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/\",\"name\":\"How to buy Intellia Therapeutics, Inc. (NTLA) shares - Investment in Intellia Therapeutics, Inc. (NTLA) stock\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"datePublished\":\"2025-08-20T10:11:08+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to buy Intellia Therapeutics, Inc. (NTLA) shares &#8211; Investment in Intellia Therapeutics, Inc. (NTLA) stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How to buy Intellia Therapeutics, Inc. (NTLA) shares - Investment in Intellia Therapeutics, Inc. (NTLA) stock","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"How to buy Intellia Therapeutics, Inc. (NTLA) shares - Investment in Intellia Therapeutics, Inc. (NTLA) stock","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-20T10:11:08+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"How to buy Intellia Therapeutics, Inc. (NTLA) shares &#8211; Investment in Intellia Therapeutics, Inc. (NTLA) stock","datePublished":"2025-08-20T10:11:08+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/"},"wordCount":17,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/","name":"How to buy Intellia Therapeutics, Inc. (NTLA) shares - Investment in Intellia Therapeutics, Inc. (NTLA) stock","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","datePublished":"2025-08-20T10:11:08+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-intellia-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"How to buy Intellia Therapeutics, Inc. (NTLA) shares &#8211; Investment in Intellia Therapeutics, Inc. (NTLA) stock"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":340096,"slug":"how-to-buy-intellia-therapeutics","post_title":"Comment acheter des actions Intellia Therapeutics, Inc. (NTLA) - Investissement dans les actions Intellia Therapeutics, Inc. (NTLA)","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/"},"it_IT":{"locale":"it_IT","id":340101,"slug":"how-to-buy-intellia-therapeutics","post_title":"Come acquistare azioni Intellia Therapeutics, Inc. (NTLA) - Investire in azioni Intellia Therapeutics, Inc. (NTLA)","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/signal\/how-to-buy-intellia-therapeutics\/"},"pl_PL":{"locale":"pl_PL","id":340099,"slug":"how-to-buy-intellia-therapeutics","post_title":"Jak kupi\u0107 akcje Intellia Therapeutics, Inc. (NTLA) - Inwestycja w akcje Intellia Therapeutics, Inc. (NTLA)","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/signal\/how-to-buy-intellia-therapeutics\/"},"es_ES":{"locale":"es_ES","id":340103,"slug":"how-to-buy-intellia-therapeutics","post_title":"C\u00f3mo comprar acciones de Intellia Therapeutics, Inc. (NTLA) - Inversi\u00f3n en acciones de Intellia Therapeutics, Inc. (NTLA)","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/signal\/how-to-buy-intellia-therapeutics\/"},"th_TH":{"locale":"th_TH","id":340100,"slug":"how-to-buy-intellia-therapeutics","post_title":"\u0e27\u0e34\u0e18\u0e35\u0e0b\u0e37\u0e49\u0e2d\u0e2b\u0e38\u0e49\u0e19 Intellia Therapeutics, Inc. (NTLA) - \u0e01\u0e32\u0e23\u0e25\u0e07\u0e17\u0e38\u0e19\u0e43\u0e19\u0e2b\u0e38\u0e49\u0e19 Intellia Therapeutics, Inc. (NTLA)","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/signal\/how-to-buy-intellia-therapeutics\/"},"tr_TR":{"locale":"tr_TR","id":340102,"slug":"how-to-buy-intellia-therapeutics","post_title":"Intellia Therapeutics, Inc. (NTLA) Hisseleri Nas\u0131l Al\u0131n\u0131r - Intellia Therapeutics, Inc. (NTLA) Hisse Senedi Yat\u0131r\u0131m\u0131","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-intellia-therapeutics\/"},"vt_VT":{"locale":"vt_VT","id":340098,"slug":"how-to-buy-intellia-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Intellia Therapeutics, Inc. (NTLA) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Intellia Therapeutics, Inc. (NTLA)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-intellia-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":340097,"slug":"how-to-buy-intellia-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Intellia Therapeutics, Inc. (NTLA) - Investimento em a\u00e7\u00f5es da Intellia Therapeutics, Inc. (NTLA)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-intellia-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/340066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=340066"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/340066\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/334072"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=340066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=340066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=340066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}